| scholarly article | Q13442814 |
| P50 | author | Brian R. Murphy | Q65658906 |
| David Swayne | Q67293866 | ||
| P2093 | author name string | Alexander G Pletnev | |
| Alexander A Rumyantsev | |||
| Jim Speicher | |||
| P2860 | cites work | Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein | Q37596501 |
| Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys | Q40500583 | ||
| Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors | Q40511346 | ||
| rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers | Q40515729 | ||
| Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus | Q40549292 | ||
| Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells | Q40549813 | ||
| Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells | Q40575878 | ||
| Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. | Q40593118 | ||
| Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice | Q40707919 | ||
| The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice | Q40722416 | ||
| Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3' deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice | Q40814578 | ||
| West Nile virus | Q64127859 | ||
| Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes | Q24289053 | ||
| Epidemiology and transmission dynamics of West Nile virus disease | Q24603195 | ||
| Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys | Q27469474 | ||
| Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus | Q27469831 | ||
| Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice | Q27469872 | ||
| Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in Mosquitoes | Q27469955 | ||
| West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy | Q27471660 | ||
| Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc Receptor-Dependent and -Independent Mechanisms | Q27472823 | ||
| A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice | Q27472824 | ||
| A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys | Q27473080 | ||
| Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4 | Q27480832 | ||
| Fatal Encephalitis and Myocarditis in Young Domestic Geese (Anser anser domesticus) Caused by West Nile Virus | Q27487812 | ||
| West Nile virus vaccines | Q34335105 | ||
| ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy | Q34362322 | ||
| West Nile virus: epidemiology and ecology in North America | Q35625021 | ||
| Recent advances in the molecular biology of west nile virus | Q36352339 | ||
| Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y. | Q36827663 | ||
| P433 | issue | 40-41 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| West Nile virus | Q158856 | ||
| Dengue virus | Q476209 | ||
| P1104 | number of pages | 13 | |
| P304 | page(s) | 6392-6404 | |
| P577 | publication date | 2006-06-21 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity | |
| P478 | volume | 24 |
| Q40073429 | A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers |
| Q37336762 | A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates |
| Q39349515 | A hamster-derived West Nile virus strain is highly attenuated and induces a differential proinflammatory cytokine response in two murine cell lines |
| Q27487992 | A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells |
| Q34225723 | A recombinant chimeric La Crosse virus expressing the surface glycoproteins of Jamestown Canyon virus is immunogenic and protective against challenge with either parental virus in mice or monkeys. |
| Q37236968 | A review of vaccine approaches for West Nile virus |
| Q38866173 | An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection |
| Q37123147 | An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody |
| Q38131535 | Application of West Nile virus diagnostic techniques |
| Q33909344 | Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine. |
| Q40058547 | Attenuation of porcine reproductive and respiratory syndrome virus strain MN184 using chimeric construction with vaccine sequence |
| Q27489646 | Cellular Inflammatory Response to Flaviviruses in the Central Nervous System of a Primate Host |
| Q40354696 | Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations |
| Q27486117 | Comparative Neuropathogenesis and Neurovirulence of Attenuated Flaviviruses in Nonhuman Primates |
| Q39990565 | Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. |
| Q40420984 | Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. |
| Q90233695 | Current Progress of Avian Vaccines Against West Nile Virus |
| Q34788758 | Current trends in West Nile virus vaccine development |
| Q39364951 | Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate |
| Q27486589 | Drak2 contributes to West Nile virus entry into the brain and lethal encephalitis |
| Q30250251 | Epidemiological and clinical aspects on West Nile virus, a globally emerging pathogen. |
| Q33880730 | Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection |
| Q27487013 | Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys |
| Q27490208 | Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters |
| Q90798978 | Flavivirus infection-A review of immunopathogenesis, immunological response, and immunodiagnosis |
| Q27486407 | Identification of Mutated Cyclization Sequences That Permit Efficient Replication of West Nile Virus Genomes: Use in Safer Propagation of a Novel Vaccine Candidate |
| Q40352155 | Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate |
| Q41218531 | Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine |
| Q36780133 | Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development |
| Q35943367 | MicroRNA targeting of neurotropic flavivirus: effective control of virus escape and reversion to neurovirulent phenotype |
| Q36599056 | MicroRNA-based control of tick-borne flavivirus neuropathogenesis: Challenges and perspectives |
| Q36136167 | Microarray hybridization for assessment of the genetic stability of chimeric West Nile/dengue 4 virus |
| Q27488399 | Neuropathogenesis and Neurovirulence of Live Flaviviral Vaccines in Monkeys |
| Q28082778 | Plant-made vaccines against West Nile virus are potent, safe, and economically feasible |
| Q38266413 | RNA-based viral vectors |
| Q21284433 | Recent progress in West Nile virus diagnosis and vaccination |
| Q40383859 | RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters |
| Q37955411 | Role of γδ T cells in West Nile virus-induced encephalitis: friend or foe? |
| Q33821694 | Silencing of neurotropic flavivirus replication in the central nervous system by combining multiple microRNA target insertions in two distinct viral genome regions |
| Q36118259 | Targeted mutagenesis as a rational approach to dengue virus vaccine development |
| Q37324444 | The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers |
| Q34036778 | The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome |
| Q40217216 | The neutralizing antibody response against West Nile virus in naturally infected horses |
| Q37350360 | Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses |
| Q27490290 | Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection |
| Q93155035 | Twenty Years of Progress Toward West Nile Virus Vaccine Development |
| Q27478162 | Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1 |
| Q27329490 | Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus |
| Q37842337 | Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus |
| Q26999702 | Vaccines in development against West Nile virus |
| Q40363063 | gammadelta T cells promote the maturation of dendritic cells during West Nile virus infection |
Search more.